Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Iberdomide - Bristol Myers Squibb

Next Previous
Drug Profile

Iberdomide - Bristol Myers Squibb

Alternative Names: BMS 986382; CC-220; IBER

Latest Information Update: 18 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Celgene Corporation
  • Developer Bristol-Myers Squibb; Celgene Corporation; Emory University
  • Class Anti-inflammatories; Antineoplastics; Isoindoles; Piperidones; Skin disorder therapies; Small molecules
  • Mechanism of Action Ubiquitin protein ligase complex modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Multiple myeloma
  • Phase II Smoldering multiple myeloma
  • Phase I B-cell lymphoma; Lymphoma
  • Discontinued Atopic dermatitis; Cutaneous lupus erythematosus; Follicular lymphoma; Sarcoidosis; Systemic lupus erythematosus; Systemic scleroderma

Most Recent Events

  • 12 Jun 2025 Updated efficacy and adverse events data from the phase Ib/IIa CC-220-MM-001 trial in Multiple myeloma released by Bristol-Myers Squibb
  • 29 Apr 2025 Celgene terminates phase I trials in Lymphoma (Combination therapy, Second-line therapy or greater) in France, Germany, Italy, South Korea, Taiwan, USA due to business objective change (NCT04464798)
  • 25 Apr 2025 3898025 - updated - kdm - tu, AR, HE

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top